Krauth, Maria-Theresa

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 386

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., et al. (2018) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentLymphoma Diagnosis and Treatment

Cited by 151

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

Heinemann, T., Kornauth, C., Severin, Y., Vladimer, G. I., Pemovska, T., Hadzijusufovic, E., Agis, H., Krauth, M.-T., Sperr, W. R., Valent, P., et al. (2022) · Blood Cancer Discovery

Digital Imaging for Blood DiseasesAcute Myeloid Leukemia Research

Cited by 28